ArticleCoDAS2026
Auracast and hearing devices: a scoping review on connectivity and accessibility for individuals with hearing loss in public environments.
Article in CoDAS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo map and synthesize the available evidence on the use of Auracast technology in hearing aids (HA), in the context of auditory accessibility in public environments. RESEARCH STRATEGIES: This scoping review followed the Joanna Briggs Institute (JBI) and PRISMA-ScR guidelines. The PCC framework was adopted (Population: individuals with hearing loss using HA; Concept: Auracast technology; Context: public environments). The search strategy was based solely on the keyword "Auracast" and applied to a defined time window from June 2022 (the official launch of Auracast) to April 2025. Information sources included scientific databases (PubMed, Scopus, IEEE Xplore, Dimensions Analytics) and gray literature sources (Google Scholar, websites of HA manufacturers, professional associations, and institutional repositories such as OSF and OpenGrey). SELECTION CRITERIA: Study selection and data extraction were conducted independently and blindly by two reviewers, with disagreements resolved by consensus. DATA ANALYSIS: A total of 348 records were identified. After removing duplicates and applying eligibility criteria, 17 studies were included in the final synthesis.
resultsThe available evidence suggests that Auracast could improve accessibility and autonomy in public settings, particularly when integrated with HA. However, most studies were technical or descriptive, lacking robust clinical evaluations.
conclusionAuracast is an emerging innovation in auditory accessibility. Nevertheless, further empirical studies are needed to assess its effectiveness in educational, healthcare, and transportation settings. Large-scale adoption will depend on technical, financial, and social factors, especially in low-infrastructure contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.